- Title
- A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
- Creators
- Peter J HOSEIN - Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United StatesMichael D CRAIG - Division of Hematology/Oncology, Department of Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, United StatesMartin S TALLMAN - Memorial Sloan Kettering Cancer Center, New York, New York, United StatesRalph V BOCCIA - Center for Cancer and Blood Disorders, Bethesda, Maryland, United StatesBrian L HAMILTON - ZIOPHARM Oncology, Inc., Boston, Massachusetts, United StatesJonathan J LEWIS - ZIOPHARM Oncology, Inc., Boston, Massachusetts, United StatesIzidore S LOSSOS - Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States
- Publication Details
- American journal of hematology, Vol.87(1), pp.111-114
- Publisher
- Wiley-Liss; Hoboken, NJ
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 22081459
- Record Identifier
- 991031561084602976
Journal article
A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
American journal of hematology, Vol.87(1), pp.111-114
2012
PMID: 22081459
Metrics
11 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 3 Agriculture, Environment & Ecology
- 3.91 Contamination & Phytoremediation
- 3.91.660 Arsenic
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites